Total Payments
$700,896
2024 Payments
$192,797
Companies
38
Transactions
519
Medicare Patients
892
Medicare Billing
$308,476
Payment Breakdown by Category
Other$519,726 (74.2%)
Consulting$119,577 (17.1%)
Travel$49,741 (7.1%)
Food & Beverage$10,444 (1.5%)
Research$1,193 (0.2%)
Education$214.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $516,161 | 179 | 73.6% |
| Consulting Fee | $119,577 | 59 | 17.1% |
| Travel and Lodging | $49,741 | 82 | 7.1% |
| Food and Beverage | $10,444 | 187 | 1.5% |
| Honoraria | $3,565 | 3 | 0.5% |
| Unspecified | $1,193 | 5 | 0.2% |
| Education | $214.85 | 4 | 0.0% |
Payments by Type
General
$699,703
514 transactions
Research
$1,193
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $154,927 | 114 | $0 (2024) |
| GENZYME CORPORATION | $144,073 | 79 | $0 (2024) |
| ABBVIE INC. | $118,191 | 77 | $0 (2024) |
| Genentech USA, Inc. | $53,197 | 34 | $0 (2024) |
| BeiGene USA, Inc. | $42,344 | 20 | $0 (2024) |
| ADC Therapeutics America, Inc. | $40,276 | 28 | $0 (2024) |
| Genmab U.S., Inc. | $36,208 | 23 | $0 (2024) |
| Lilly USA, LLC | $34,705 | 25 | $0 (2024) |
| Daiichi Sankyo Inc. | $19,239 | 23 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $16,553 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $192,797 | 134 | ABBVIE INC. ($40,501) |
| 2023 | $155,758 | 130 | BeiGene USA, Inc. ($34,063) |
| 2022 | $113,026 | 66 | Incyte Corporation ($38,327) |
| 2021 | $111,653 | 64 | GENZYME CORPORATION ($31,883) |
| 2020 | $45,089 | 29 | Incyte Corporation ($17,011) |
| 2019 | $57,452 | 65 | Daiichi Sankyo Inc. ($19,155) |
| 2018 | $18,270 | 20 | GENZYME CORPORATION ($17,755) |
| 2017 | $6,851 | 11 | GENZYME CORPORATION ($4,207) |
All Payment Transactions
519 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Oncology | ||||||
| 12/13/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $6.81 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | ABBVIE INC. | EPKINLY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,064.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Travel and Lodging | In-kind items and services | $579.02 | General |
| Category: Oncology | ||||||
| 11/14/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $103.66 | General |
| Category: Oncology | ||||||
| 11/07/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $1,643.74 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $110.10 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,571.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $121.81 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.69 | General |
| Category: Hematology | ||||||
| 10/18/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $115.48 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,000.00 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $1,089.32 | General |
| 10/10/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| Category: Oncology | ||||||
| 10/10/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $831.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory Follicular Lymphoma | Regeneron Pharmaceuticals, Inc. | $1,193 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 329 | 1,150 | $441,285 | $142,810 |
| 2022 | 5 | 288 | 919 | $182,599 | $103,729 |
| 2021 | 6 | 139 | 349 | $66,218 | $32,540 |
| 2020 | 6 | 136 | 383 | $70,635 | $29,397 |
Total Patients
892
Total Services
2,801
Medicare Billing
$308,476
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 184 | 733 | $289,535 | $97,957 | 33.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 58 | 300 | $98,400 | $28,347 | 28.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 59 | 89 | $39,014 | $12,257 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $14,336 | $4,248 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 164 | 639 | $125,086 | $74,112 | 59.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 38 | 173 | $29,328 | $14,057 | 47.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 40 | 59 | $16,004 | $9,283 | 58.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $10,122 | $5,325 | 52.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 15 | $2,059 | $953.04 | 46.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 65 | 142 | $29,251 | $18,826 | 64.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 136 | $22,032 | $7,836 | 35.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 12 | 27 | $6,345 | $2,110 | 33.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 11 | 11 | $3,465 | $1,961 | 56.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 16 | 19 | $2,899 | $1,098 | 37.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 14 | $2,226 | $708.63 | 31.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 56 | 102 | $19,380 | $10,312 | 53.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 22 | 146 | $23,652 | $8,606 | 36.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 51 | $8,398 | $4,353 | 51.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 19 | 55 | $12,918 | $3,422 | 26.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 12 | 12 | $3,828 | $1,692 | 44.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 15 | 17 | $2,459 | $1,012 | 41.2% |
About Dr. Mark Fesler, MD
Dr. Mark Fesler, MD is a Internal Medicine healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235204066.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Fesler, MD has received a total of $700,896 in payments from pharmaceutical and medical device companies, with $192,797 received in 2024. These payments were reported across 519 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($516,161).
As a Medicare-enrolled provider, Fesler has provided services to 892 Medicare beneficiaries, totaling 2,801 services with total Medicare billing of $308,476. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Saint Louis, MO
- Active Since 11/21/2006
- Last Updated 03/29/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1235204066
Products in Payments
- MONJUVI (Drug) $81,224
- JAKAFI (Drug) $73,663
- MOZOBIL (Drug) $61,430
- VENCLEXTA (Drug) $55,702
- Polivy (Biological) $43,824
- SARCLISA (Biological) $40,774
- Epkinly (Drug) $36,208
- EPKINLY (Drug) $35,138
- BRUKINSA (Drug) $33,344
- JAYPIRCA (Drug) $15,091
- CALQUENCE (Drug) $8,129
- Lunsumio (Biological) $7,583
- Venclexta (Drug) $5,631
- Vonjo (Drug) $4,129
- VYXEOS (Drug) $3,200
- IMBRUVICA (Drug) $2,800
- ABECMA (Biological) $2,760
- Yescarta (Drug) $2,450
- LUMOXITI (Biological) $2,398
- clonoSEQ (Device) $2,339
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Saint Louis
Dr. John Lasala, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Katie Schroeder, Md, MD
Internal Medicine — Payments: $659,683
Internal Medicine $659,683
Edward Charbek, Md, MD
Internal Medicine — Payments: $260,967
Internal Medicine $260,967
Dr. Michael Reschak, M.d, M.D
Internal Medicine — Payments: $245,910
Internal Medicine $245,910
Dr. Osler Jay Guzon, Md, MD
Internal Medicine — Payments: $237,841
Internal Medicine $237,841
Dr. George Ansstas, Md, MD
Internal Medicine — Payments: $233,767
Internal Medicine $233,767